Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 9:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 514 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Chronic Graft Versus Host Disease Oral Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Blood Concentrations of 4 Different Oral Doses of Zibotentan in Healthy Non-Asian and Japanese Participants

NCT06715670
View directory record Official record
Conditions
Liver Cirrhosis
Interventions
Zibotentan
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Oct 15, 2026, 9:09 PM EDT
Completed Not applicable Interventional

Novel PAradigm to Improve Inflammatory Burden in ESRD (rePAIR): A Pilot and Feasibility Randomized Controlled Trial

NCT03241511
View directory record Official record
Conditions
Chronic Periodontitis, End Stage Renal Disease
Interventions
Test
Other
Lead sponsor
UConn Health
Other
Eligibility
21 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Oct 15, 2026, 9:09 PM EDT
Completed Phase 2 Interventional Results available

16-Week Repeat Oral Dose Study of AKB-6548 for Anemia in Participants With End Stage Renal Disease (ESRD) Requiring Chronic Hemodialysis

NCT02260193
View directory record Official record
Conditions
Anemia, End Stage Renal Disease
Interventions
AKB-6548
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years to 79 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
16
States / cities
El Granada, California • Long Beach, California • San Dimas, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2022 · Synced Oct 15, 2026, 9:09 PM EDT
Terminated Phase 4 Interventional

Determination of Rates and Reasons for Non-Adherence to Anti-Arrhythmic Therapy for Atrial Fibrillation

NCT01513031
View directory record Official record
Conditions
Atrial Fibrillation, Medication Adherence
Interventions
Education and telephone follow-up
Other
Lead sponsor
Creighton University
Other
Eligibility
19 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
3
States / cities
Lincoln, Nebraska • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jul 2, 2012 · Synced Oct 15, 2026, 9:09 PM EDT
Completed Not applicable Interventional Results available

Oral Steroids in Chronic Rhinosinusitis Without Nasal Polyps

NCT02927834
View directory record Official record
Conditions
Sinusitis
Interventions
6 day Prednisone, Augmentin, 21 day Prednisone
Drug
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Dec 29, 2020 · Synced Oct 15, 2026, 9:09 PM EDT
Completed No phase listed Observational

Predicting Oxycodone Dose From Oral Fluid Drug Levels

NCT01928303
View directory record Official record
Conditions
Chronic Pain
Interventions
Not listed
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 72 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 15, 2014 · Synced Oct 15, 2026, 9:09 PM EDT
Completed Phase 2 Interventional Results available

A Clinical Trial to Evaluate the Safety and Efficacy in Subjects With Chronic Cough

NCT05392192
View directory record Official record
Conditions
Chronic Cough
Interventions
ADX-629, Placebo
Drug
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
14
States / cities
San Diego, California • San Jose, California • Hollywood, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2025 · Synced Oct 15, 2026, 9:09 PM EDT
Completed Phase 3 Interventional

A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine

NCT04686136
View directory record Official record
Conditions
Episodic Migraine, Chronic Migraine
Interventions
Atogepant 60 mg
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 80 Years
Enrollment
596 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
42
States / cities
Phoenix, Arizona • Fresno, California • Los Alamitos, California + 35 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 15, 2026, 9:09 PM EDT
Completed Phase 3 Interventional

Effect of Adjunctive Treatment With Arestin on the Subgingival Microflora in Patients With Moderate to Advanced Periodontitis

NCT00371332
View directory record Official record
Conditions
Periodontitis
Interventions
Minocycline HCL Microspheres
Drug
Lead sponsor
OraPharma
Industry
Eligibility
30 Years to 65 Years
Enrollment
128 participants
Timeline
Started 2004
U.S. locations
5
States / cities
Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2006 · Synced Oct 15, 2026, 9:09 PM EDT
Completed Phase 4 Interventional Results available

Repeated-dose Safety, Efficacy, Pharmacokinetic and Pharmacodynamic of CTAP101, Immediate-release Calcifediol, High-dose Cholecalciferol, and Paricalcitol Plus Low-dose Cholecalciferol in Patients With Secondary Hyperparathyroidism, Chronic Kidney Disease 3-4 and Vitamin D Insufficiency

NCT03588884
View directory record Official record
Conditions
Secondary Hyperparathyroidism Due to Renal Causes, Vitamin D Insufficiency, CKD Stage 3, CKD Stage 4
Interventions
Calcifediol Oral Capsule, Calcifediol Oral Product, Cholecalciferol, Paricalcitol Oral Capsule
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
3
States / cities
Garden Grove, California • Chicago, Illinois • West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 9, 2022 · Synced Oct 15, 2026, 9:09 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Dental Intervention Plan for Chronic Kidney Disease Patients Awaiting or With Kidney Transplant

NCT04020458
View directory record Official record
Conditions
Chronic Kidney Disease, Chronic Periodontitis, Generalized, Moderate
Interventions
dental intervention
Procedure
Lead sponsor
Augusta University
Other
Eligibility
21 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 21, 2023 · Synced Oct 15, 2026, 9:09 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of 4 Weeks Treatment With Inhaled BI 1744 CL in Patients With COPD.

NCT00452400
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, Asthma
Interventions
BI 1744CL
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
409 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
22
States / cities
Birmingham, Alabama • Lakewood, California • Denver, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2014 · Synced Oct 15, 2026, 9:09 PM EDT
Completed Phase 3 Interventional Results available

Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine

NCT05216263
View directory record Official record
Conditions
Chronic Migraine
Interventions
Atogepant
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
29
States / cities
Hoover, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 15, 2026, 9:09 PM EDT
Terminated Not applicable Interventional

Domperidone for Relief of Gastrointestinal Disorders

NCT00761254
View directory record Official record
Conditions
Gastroparesis, GERD, Esophagitis, Dyspepsia, Chronic Idiopathic Constipation, Nausea, Vomiting
Interventions
Domperidone
Drug
Lead sponsor
Carle Physician Group
Individual
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Urbana, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 13, 2012 · Synced Oct 15, 2026, 9:09 PM EDT
Completed Phase 1 Interventional

Study of Oral LOXO-338 in Patients With Advanced Blood Cancers

NCT05024045
View directory record Official record
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-cell Marginal Zone, Lymphoma, Non-Hodgkin, Multiple Myeloma, B-cell Lymphoma, Waldenstrom Macroglobulinemia, Lymphoma, Mantle-Cell
Interventions
LOXO-338, Pirtobrutinib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
13
States / cities
Tucson, Arizona • Duarte, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 15, 2026, 9:09 PM EDT
Terminated Phase 1 Interventional

Prospective L-arginine Study

NCT01485757
View directory record Official record
Conditions
Heart Transplant
Interventions
L-arginine
Drug
Lead sponsor
University of Michigan
Other
Eligibility
8 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 10, 2017 · Synced Oct 15, 2026, 9:09 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of EDP-978 in Healthy Adults

NCT07540910
View directory record Official record
Conditions
Chronic Inducible Urticaria, Chronic Spontaneous Urticaria
Interventions
EDP-978, Placebo
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 15, 2026, 9:09 PM EDT
Completed Phase 3 Interventional Results available

12 / 48 Week Pivotal PFT vs PBO in COPD I

NCT00782210
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Olodaterol (BI1744), placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
625 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
21
States / cities
Jasper, Alabama • Berkeley, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2014 · Synced Oct 15, 2026, 9:09 PM EDT
Completed Phase 2 Interventional Results available

Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS)

NCT01842646
View directory record Official record
Conditions
Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML)
Interventions
PF-04449913
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 15, 2026, 9:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess CYP3A4 Modulator, Oral Contraceptive, and pH Modifier Drug Interactions for ABI-H2158 in Healthy Adults

NCT04142762
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
ABI-H2158, Itraconazole, Rifampin, Midazolam, Ethinyl Estradiol / Levonorgestrel, Esomeprazole, Placebo matching oral contraceptive
Drug
Lead sponsor
Assembly Biosciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced Oct 15, 2026, 9:09 PM EDT
Completed Phase 3 Interventional Results available

Open-Label and Single-Arm Study of MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adults

NCT02610868
View directory record Official record
Conditions
Sialorrhea
Interventions
MYOBLOC
Drug
Lead sponsor
Solstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLC
Industry
Eligibility
18 Years to 85 Years
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
26
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Loma Linda, California + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 15, 2026, 9:09 PM EDT
Completed Phase 1 Interventional

Thalidomide and Docetaxel in Treating Patients With Advanced Cancer

NCT00049296
View directory record Official record
Conditions
Cancer
Interventions
docetaxel, thalidomide
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 11, 2010 · Synced Oct 15, 2026, 9:09 PM EDT
Completed Phase 3 Interventional Results available

Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer

NCT00661999
View directory record Official record
Conditions
Anemia, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
darbepoetin alfa, ferrous sulfate, sodium ferric gluconate complex in sucrose, placebo
Biological · Dietary Supplement · Drug + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
502 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 17, 2011 · Synced Oct 15, 2026, 9:09 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Low-dose Oral Clofarabine for the Treatment of IPSS INT-1, INT-2 or HIGH Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia

NCT00708721
View directory record Official record
Conditions
Cancer, Chronic Myelomonocytic Leukemia
Interventions
Clofarabine
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 1, 2017 · Synced Oct 15, 2026, 9:09 PM EDT